| 253.07 4.71 (1.9%) | 08-18 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 309.57 |
1-year : | 361.58 |
| Resists | First : | 265.04 |
Second : | 309.57 |
| Pivot price | 253.39  |
|||
| Supports | First : | 245.52 |
Second : | 233.46 |
| MAs | MA(5) : | 248.23 |
MA(20) : | 253.61 |
| MA(100) : | 228.12 |
MA(250) : | 184.94 |
|
| MACD | MACD : | 1.3 |
Signal : | 2.8 |
| %K %D | K(14,3) : | 33.4 |
D(3) : | 23.2 |
| RSI | RSI(14): 54.2 |
|||
| 52-week | High : | 265.04 | Low : | 118.04 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ JAZZ ] has closed above bottom band by 48.4%. Bollinger Bands are 8.4% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 256.65 - 257.64 | 257.64 - 258.77 |
| Low: | 246.06 - 247.11 | 247.11 - 248.32 |
| Close: | 251.1 - 252.8 | 252.8 - 254.76 |
Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.
Sat, 15 Aug 2026
Jazz Pharmaceuticals PLC at TD Cowen Oncology Innovation Summit (Virtual) Transcript - GuruFocus
Fri, 14 Aug 2026
Jazz Pharmaceuticals PLC $JAZZ Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Thu, 13 Aug 2026
Jazz Pharmaceuticals (JAZZ) Stock Looks Cheap On Earnings While Broader Checks Stay Mixed - simplywall.st
Wed, 12 Aug 2026
Jazz Pharmaceuticals Bolsters Epilepsy Division With Actio Biosciences Buyout (JAZZ) - Seeking Alpha
Wed, 12 Aug 2026
Wedge Capital Management L L P NC Sells 33,467 Shares of Jazz Pharmaceuticals PLC $JAZZ - MarketBeat
Mon, 10 Aug 2026
Jazz bets on epilepsy treatment with up to $1.32 billion deal for Actio - Reuters
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Outperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 65 (M) |
| Shares Float | 63 (M) |
| Held by Insiders | 2.9 (%) |
| Held by Institutions | 105 (%) |
| Shares Short | 3,800 (K) |
| Shares Short P.Month | 3,940 (K) |
| EPS | 14.61 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 72.29 |
| Profit Margin | 20.4 % |
| Operating Margin | 26.9 % |
| Return on Assets (ttm) | 6.8 % |
| Return on Equity (ttm) | 22.1 % |
| Qtrly Rev. Growth | 15.5 % |
| Gross Profit (p.s.) | 64.7 |
| Sales Per Share | 70.86 |
| EBITDA (p.s.) | 29.73 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 1,660 (M) |
| Levered Free Cash Flow | 1,430 (M) |
| PE Ratio | 17.3 |
| PEG Ratio | 0.9 |
| Price to Book value | 3.5 |
| Price to Sales | 3.57 |
| Price to Cash Flow | 9.89 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|